Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

40.83 -0.03 (-0.07%)
Streaming Delayed Price Updated: 1:30 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gsk Plc ADR

< Previous 1 2 3 Next >
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
From BELLUS Health Inc.
Via Business Wire
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug 
Via MarketBeat
International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment
From HKTDC
Via ACN Newswire
US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
From GSK plc
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
From BELLUS Health Inc.
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy -- Adaptimmune and GSK will... 
Via Newsfile
Back from the Dead, IBM’s Watson AI is Alive and Re-Emerging
While artificial intelligence (AI) seems to have come around full circle in 2023 as ChatGPT finally lit the fuse for full-blown mainstream adoption, Internat 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
SCYNEXIS (NASDAQ: SCYX) Enters Into Exclusive Agreement with GSK (NYSE: GSK) to Continue Commercializing Brexafemme to Treat Fungal Infections
SCYNEXIS, Inc. (NASDAQ: SCYX) operates as a biotechnology company, which is focused on the research and development of novel solutions 
Via Spotlight Growth
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade. 
Via MarketBeat
GSK and Earvin “Magic” Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
From GSK plc
Via Business Wire
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:AZN),(NYSE:BMY),(NYSE:AMAM),(NYSE:GSK) EQNX::TICKER_END 
Via FinancialNewsMedia
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
How Could GSK's RSV Vaccine Change its Valuation?
GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future. 
Via MarketBeat
Exposures Product Safety
The Year of the Tripledemic
COVID-19 may have lost its daily news headline status, but the disease rages on with 2700 weekly deaths in the U.S. and millions of Americans chronically disabled from long-COVID, 4 million of which... 
Via TheNewswire.com
Topics Death
Exposures COVID-19 Death Product Safety
Big Health Care Stocks to Watch in the New Year
Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now. 
Via MarketBeat
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients
From GSK plc
Via Business Wire
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months. 
Via MarketBeat
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
From Singapore Economic Development Board (EDB)A*STAR
Via ACN Newswire
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Cosmos Holdings stock is up 618% in November likely due to a short squeeze. This article explains why Cosmos Holdings may still be a good long-term investment 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
GSK Plc (NYSE:GSK) Investor Alert: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 10/21/2022 -- An investigation was announced on behalf of investors in NYSE:GSK shares over potential breaches of fiduciary duties by certain officers and directors at GSK... 
Via SBWire
Is Pfizer Stock Still Worth Buying After the Pandemic?
Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations. 
Via MarketBeat
Exposures COVID-19
Spero Therapeutics (NASDAQ: SPRO) Enters into Exclusive Licensing Agreement with GSK (NYSE: GSK) for the Commercialization of Tebipenem HBr
Spero Therapeutics, Inc. (NASDAQ: SPRO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and 
Via Spotlight Growth
Exposures Product Safety
Is Sanofi A Buy, Despite Recent Stumbles?
Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in GSK plc with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.